--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About IMRX20260220C7.5
Biological Technology
Immuneering Corporation was incorporated in Delaware in 2008. The Company is a clinical-stage oncology company seeking to develop and commercialize generic RAS/RAF drugs for a broad population of cancer patients. The company's goal is to achieve this universal RAS/RAF activity through deep circulatory inhibition of the MAPK pathway, impacting cancer cells while preserving healthy cells. The company's inclusive approach distinguishes the company from narrowly targeted precision therapies, which are limited to tumor patients with specific mutations.
